KRSANasdaqPharmaceutical PreparationsFiscal year ends December 31
Korsana Biosciences, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026
$31.41−0.97 (-3.00%)
Close on Oct 19, 2026
- Market cap
- $133.52M
- P/E (TTM)
- –
- Dividend yield
- –
Korsana Biosciences, Inc. revenue by segment
By business segment
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | % of revenue | YoY |
|---|---|---|---|---|---|
| Revenue from license agreement | $1.00M | $1.75M | $0 | 48.2% | -42.9% |
| Revenue from purchase agreement | $800.00K | $0 | – | 38.6% | – |
| Option Agreement [Member] | $274.00K | $250.00K | – | 13.2% | +9.6% |
| Option to license revenue | – | $250.00K | $0 | – | – |
By region
From the segment and revenue-disaggregation notes of Korsana Biosciences's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.